Trial Profile
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 08 Sep 2020 Status changed from active, no longer recruiting to completed.
- 30 May 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2016 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.